BRPI0813630A2 - combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e) - Google Patents

combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)

Info

Publication number
BRPI0813630A2
BRPI0813630A2 BRPI0813630A BRPI0813630A BRPI0813630A2 BR PI0813630 A2 BRPI0813630 A2 BR PI0813630A2 BR PI0813630 A BRPI0813630 A BR PI0813630A BR PI0813630 A BRPI0813630 A BR PI0813630A BR PI0813630 A2 BRPI0813630 A2 BR PI0813630A2
Authority
BR
Brazil
Prior art keywords
cd49e
integrin
antibody
beta
alpha
Prior art date
Application number
BRPI0813630A
Other languages
English (en)
Inventor
Ramakrishnan Vanitha
Bhaskar Vinay
Original Assignee
Facet Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facet Biotech Corp filed Critical Facet Biotech Corp
Publication of BRPI0813630A2 publication Critical patent/BRPI0813630A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
BRPI0813630A 2007-07-27 2008-07-28 combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e) BRPI0813630A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95232807P 2007-07-27 2007-07-27
PCT/US2008/071379 WO2009018226A2 (en) 2007-07-27 2008-07-28 Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)

Publications (1)

Publication Number Publication Date
BRPI0813630A2 true BRPI0813630A2 (pt) 2019-09-24

Family

ID=40291258

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813630A BRPI0813630A2 (pt) 2007-07-27 2008-07-28 combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)

Country Status (9)

Country Link
US (1) US20090041767A1 (pt)
EP (1) EP2193148A2 (pt)
JP (1) JP2010534685A (pt)
KR (1) KR20100040877A (pt)
AU (1) AU2008282331A1 (pt)
BR (1) BRPI0813630A2 (pt)
CA (1) CA2694644A1 (pt)
MX (1) MX2010000997A (pt)
WO (1) WO2009018226A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2255792A1 (en) * 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
US8916574B2 (en) * 2009-09-28 2014-12-23 Qilu Pharmaceutical Co., Ltd. 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
EP2688585B1 (en) 2011-03-23 2018-09-05 The Regents of The University of California Methods and compositions for improving antiangiogenic therapy with anti-integrins
IN2014DN07474A (pt) * 2012-02-16 2015-04-24 Capnia Inc
CN103656656A (zh) * 2013-12-18 2014-03-26 北京科源创欣科技有限公司 甲苯磺酸索拉非尼药物组合物及制备方法
CN109311956A (zh) 2015-08-25 2019-02-05 伊斯迪德股份公司 诱导组织形成的化合物及其应用
CN109715191A (zh) * 2015-09-17 2019-05-03 伊斯迪德股份公司 将赘生性细胞转化成非赘生性细胞的药物缔合物及其用途
CN109715190A (zh) * 2015-09-17 2019-05-03 伊斯迪德股份公司 将赘生性细胞转化成非赘生性细胞的生长因子受体激动剂和黏附蛋白抑制剂的药物缔合物及其用途
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) * 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0531472T3 (da) * 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
WO1993017106A1 (en) * 1992-02-19 1993-09-02 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69333209T2 (de) * 1992-10-29 2004-07-01 The Australian National University, Acton Angiogenese-inhibierende antikörper
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
EP1575516B1 (en) * 2002-11-26 2012-05-30 Abbott Biotherapeutics Corp. Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis
JP2007524605A (ja) * 2003-04-03 2007-08-30 ピーディーエル バイオファーマ，インコーポレイティド インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用
DK1755659T3 (da) * 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
PT1989231E (pt) * 2006-03-21 2015-09-18 Genentech Inc Terapêutica combinatória que envolve antagonistas alfa5beta1
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof

Also Published As

Publication number Publication date
MX2010000997A (es) 2010-03-31
US20090041767A1 (en) 2009-02-12
JP2010534685A (ja) 2010-11-11
WO2009018226A2 (en) 2009-02-05
CA2694644A1 (en) 2009-02-05
KR20100040877A (ko) 2010-04-21
WO2009018226A3 (en) 2009-04-02
AU2008282331A1 (en) 2009-02-05
EP2193148A2 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
BRPI0813630A2 (pt) combinações farmacêuticas compreendendo inibidor da tirosina quinase e anticorpo contra a integrina alfa 1 beta 5 (cd49e)
BRPI0717367A2 (pt) Di-hidropirazolonas substituídas e sua aplicação.
DE602007014297D1 (de) Kontaktfreie Mehrbereichssonde
BRPI0811805A2 (pt) "artigo absorvente alongado e método para sua fabricação".
BRPI0714539A2 (pt) "formas farmacêuticas"
BRPI0807907A2 (pt) co-cristais e composições farmacêuticas compreendendo os mesmos.
ATE517097T1 (de) Thiazol- und oxazolsubstituierte arylamide
FI20055150A (fi) Sakeuden muuttaminen ja mittaaminen
BRPI0810581A2 (pt) Produto refratário fundido e moldado e utilização de um produto
BRPI0920850A2 (pt) novos compostos e sua utilização
DK3181691T3 (da) Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme
FI20071030A0 (fi) Off-line -vastauskortti ja järjestely vastauksen kyselemiseksi vastauskortilta
ITMI20070437U1 (it) "baldacchino ad alta fedelta'"
UA14823S (uk) Кутовий диван-ліжко «зевс»
UA15095S (uk) Диван м'який «айленд»
UA13769S (uk) Диван «кармен»
UA14053S (uk) Диван «248»
UA14810S (uk) Диван «парадіз»
UA14058S (uk) Диван «243»
UA14057S (uk) Диван «211»
UA14395S (uk) Диван «юдит»
UA14052S (uk) Диван «256»
UA14229S (uk) Диван «Vitalistyle»
UA15122S (uk) Диван кутовий «марсель»
UA13956S (uk) Комплект етикеток «kalganoff» настоянка з клюквою»

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.